U.S., Dec. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07291635) titled 'Phase 1/2 Study of a Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine' on Nov. 26.
Brief Summary: This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Influenza
Intervention:
BIOLOGICAL: Recombinant Influenza vaccine candidate
Plant-Based Seasonal Recombinant Trivalent TVLP Influenza Vaccine
BIOLOGICAL: Commercial Influenza vaccine
Influenza vaccine commercially avail...